Validation of an RNA cell cycle progression score for predicting @entity204 from XXXX in a conservatively managed needle biopsy cohort.

@entity1 @entity6585 @entity204 @entity263
BACKGROUND: The natural history of @entity263 is highly variable and difficult to predict accurately. Better markers are needed to guide management and avoid unnecessary treatment. In this study, we validate the prognostic value of a cell cycle progression score (CCP score) independently and in a prespecified linear combination with standard clinical variables, that is, a clinical-cell-cycle-risk (CCR) score. METHODS: Paraffin sections from 761 @entity1 with clinically localized @entity263 diagnosed by needle biopsy and managed conservatively in the United Kingdom, mostly between 2000 and 2003. The primary end point was @entity263 @entity204 . Clinical variables consisted of centrally reviewed Gleason score, baseline PSA level, age, clinical stage, and extent of disease; these were combined into a single predefined risk assessment (CAPRA) score. Full data were available for 585 @entity1 who formed a fully independent validation cohort. RESULTS: In univariate analysis, the CCP score hazard ratio was 2.08 (95% CI (1.76, 2.46), @entity6585 (-13)) for one unit change of the score. In multivariate analysis including CAPRA, the CCP score hazard ratio was 1.76 (95% CI (1.44, 2.14), @entity6585 (-6)). The predefined CCR score was highly predictive, hazard ratio 2.17 (95% CI (1.83, 2.57),   (2)=89.0, @entity6585 (-20)) and captured virtually all available prognostic information. CONCLUSIONS: The CCP score provides significant pretreatment prognostic information that cannot be provided by clinical variables and is useful for determining which @entity1 can be safely managed conservatively, avoiding radical treatment.
